Antonio Drago
Drago, Antonio 1976-
VIAF ID: 307341303 (Personal)
Permalink: http://viaf.org/viaf/307341303
Preferred Forms
- 100 0 _ ‡a Antonio Drago
- 200 _ 1 ‡a Drago ‡b , Antonio ‡f <1976- >
- 100 1 _ ‡a Drago, Antonio ‡d 1976-
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
The 8th annual pharmacogenetics in psychiatry meeting report | |
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. | |
DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. | |
DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. | |
Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D. | |
Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder | |
Epistasis between IL1A, IL1B, TNF, HTR2A, 5-HTTLPR and TPH2 variations does not impact alcohol dependence disorder features | |
Focus on HTR2C: A possible suggestion for genetic studies of complex disorders | |
Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls | |
A genetic perspective on antipsychotic phenotypes and response to treatment : strategies for an integrated view / Antonio Drago ; supervisore: Alessandro Serretti ; direttore della Scuola di dottorato: Marco Rigatelli | |
Genetic variations within metalloproteinases impact on the prophylaxis of depressive phases in bipolar patients | |
The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample | |
The genetics of vascular incidents associated with second-generation antipsychotic administration | |
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. | |
Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol | |
Hippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis | |
HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory | |
HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies | |
The impact of heat shock protein 70 gene variations on clinical presentation and outcome in schizophrenic inpatients. | |
Incomplete coverage of candidate genes: a poorly considered bias | |
Insight gained from genome-wide interaction and enrichment analysis on weight gain during citalopram treatment. | |
Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment | |
Investigation of an epistastic effect between a set of TAAR6 and HSP-70 genes variations and major mood disorders. | |
Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta). | |
Mechanisms of antidepressant action: an integrated dopaminergic perspective | |
The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades | |
A model to investigate SNPs' interaction in GWAS studies | |
The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes | |
Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain | |
A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment. | |
A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment. | |
A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia. | |
No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample | |
No association of a set of candidate genes on haloperidol side effects | |
Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms | |
Pharmacogenomics of Depression | |
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway | |
The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes | |
Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. | |
Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial | |
Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials | |
Strategy for a genetic assessment of antipsychotic and antidepressant-related proarrhythmia | |
TAAR 6 and HSP-70 variations associated with bipolar disorder. | |
TAAR6 variations possibly associated with antidepressant response and suicidal behavior. | |
Videoconferencing in psychiatry, a meta-analysis of assessment and treatment |